Only around 20% of the human proteome is considered to be druggable with small-molecule
antagonists. This leaves some of the most compelling therapeutic targets outside the reach …

Single-particle cryogenic electron microscopy (cryo-EM) has been elevated to the
mainstream of structural biology propelled by technological advancements in numerous …

Targeted protein degradation (TPD) is an emerging modality for research and therapeutics.
Most TPD approaches harness cellular ubiquitin-dependent proteolytic pathways …

Introduction Target protein degradation (TPD) provides a novel therapeutic modality, other
than inhibition, through the direct depletion of target proteins. Two primary human protein …

Molecular Glues, here defined as small molecules that interact with two protein surfaces to
induce or enhance affinity of these two proteins to each other, have received substantial …

Drug resistance is one of the biggest challenges in cancer treatment and limits the potential
to cure patients. In many tumors, sustained activation of the protein NRF2 makes tumor cells …

The therapeutic modality of targeted protein degradation promises to overcome limitations of
traditional pharmacology. Small-molecule degraders recruit disease-causing proteins to E3 …

Emergence of resistance is a major factor limiting the efficacy of molecularly targeted
anticancer drugs. Understanding the specific mutations, or other genetic or cellular changes …

High-throughput sequencing and functional characterization of the cancer transcriptome
have uncovered cancer-specific dysregulation of RNA splicing across a variety of cancers …

Targeted protein degradation (TPD) is emerging as a strategy to overcome the limitations of
traditional small-molecule inhibitors. Proteolysis targeting chimera (PROTAC) technology …